Pfizer Inc. and Domain Therapeutics enter into a collaboration agreement on bioSensAll™
Proprietary technology will be used to profile signaling of mutant GPCRs in order to improve and accelerate the validation of novel GPCR drug targets
Strasbourg, France, and Montreal, Canada, April 25, 2017 – Domain Therapeutics, a France- and Quebec-based biopharmaceutical company specializing in the research and development of new drug candidates that target G protein-coupled receptors (GPCRs), today announced a collaboration agreement with Pfizer Inc. (Pfizer; NYSE:PFE) aimed at assessing the impact of mutations on different signaling pathways engaged by GPCRs. Pfizer has interest in GPCRs with potential therapeutic relevance and Domain Therapeutics will use its proprietary bioSensAll™ technology to define signaling signatures for each wild-type and mutant receptors.
This collaboration aims to validate potential targets across a range of therapeutic indications by probing the structure-function relationships of various amino acid substitutions in each GPCRs. Pfizer will utilize the results of specific mutations on intracellular signaling to guide further investigations in disease-specific models.
“We are very pleased to have signed this collaboration with Pfizer for the profiling of mutant GPCRs using the bioSensAll™ platform. It is yet another example of the wide applications of the technology, from target validation through to drug discovery and development,” said Pascal Neuville, chief executive officer of Domain Therapeutics. “By building a better understanding of the signaling profile needed for efficacy, bioSensAll™ may reduce the attrition rate of early-stage drug development.”
Domain Therapeutics NA Inc, the Canadian affiliate of Domain Therapeutics, will use bioSensAll™ to characterize the basal activities and signaling profile of known ligands of wild type receptors. It will then compare these profiles with those of mutant GPCRs. These differential signaling signatures will be used to inform target validation for different therapeutic indications.
The bioSensAll™ technology allows for easier understanding of signaling pathways activated by each candidate molecule, thus predicting its pharmacological profile. This approach makes it possible to choose at an early stage of drug development those molecule(s) that have the required activity but do not present side effects or induce tolerance to treatment.